http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-11201903155X-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6df6a18e06ae0e6132770a6504815566
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate 2017-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec27b508d393c66f57399587103d1d4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ff5e4ee064e398925ea0e41f191dd28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349812a979d965782b130b974841ba8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_add04a811c2f40407ea062b587be52dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b64ca8a7cb6fc1ae43e95522ee638de6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fea6f28212ac304af5989c025dc0f6a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c9ef6887b214795023f1d5d5bd1f10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7ceaab05fc45a605736b1368aae7f36
publicationDate 2019-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-11201903155X-A
titleOfInvention Pharmaceutical compounds
abstract INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT ill 1111u°11101VIIIVIIIVIIIolo olomll Em Immo oimIE (10) International Publication Number WO 2018/073586 Al (51) International Patent Classification: CO7D 413/14 (2006.01) A61K 31/422 (2006.01) CO7D 471/04 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/GB2017/053152 (22) International Filing Date: 18 October 2017 (18.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1617630.7 18 October 2016 (18.10.2016) GB (71) Applicant: CELLCENTRIC LTD [GB/GB]; Chester- ford Research Park, Little Chesterford, Cambridge Cam- bridgeshire CB10 1XL (GB). (72) Inventors: PEGG, Neil Anthony; c/o CellCentric Lim- ited, Chesterford Research Park, Little Chesterford, Cam- bridge Cambridgeshire CB10 1XL (GB). ONIONS, Stu- art Thomas; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). TADDEI, David Michel Adrien; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). SHANNON, Jonathan; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). PAO- LETTA, Silvia; c/o Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham Nottinghamshire NG1 1GF (GB). BROWN, Richard James; c/o Sygnature Discov- ery Limited, BioCity, Pennyfoot Street, Nottingham Not- tinghamshire NG1 1GF (GB). SMYTH, Don; c/o Sygna- ture Discovery Limited, BioCity, Pennyfoot Street, Not- tingham Nottinghamshire NG1 1GF (GB). HARBOTTLE, Gareth; c/o Sygnature Discovery Limited, BioCity, Penny- foot Street, Nottingham Nottinghamshire NG1 1GF (GB). (74) Agent: KEEN, Celia Mary; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 2 I (3)) (54) Title: PHARMACEUTICAL COMPOUNDS W O 20 18/07 35 86 Al (I) (57) : A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
priorityDate 2016-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100684945
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408088710
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2033
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9254
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID170915
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID328572
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID112446776
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID458862
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID418000

Total number of triples: 40.